All In Biotech

Drug Trial Radar · NCT05281328

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver Disease

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

71

Actual

Start

Jun 28, 2022

Primary completion

Feb 5, 2025

Study completion Aug 2027

Sponsor

Lead sponsor
Camurus ABIndustry
Sponsor type
Industry
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial is to compare the effectiveness and safety of 2 treatment regimens of CAM2029 (given weekly or every 2 weeks) to placebo in participants with symptomatic PLD, either isolated as in autosomal dominant PLD (ADPLD) or associated with autosomal dominant polycystic kidney disease (ADPKD). In the Treatment Period of the trial, participants will be allocated at random to 1 of the 3 treatment arms in a 1:1:1 ratio. After completing the Treatment Period (53 weeks) participants may proceed to a 120-week open-label extension part of the trial and then only receive the same CAM2029 treatment. The active ingredient in CAM2029, octreotide, is administered as a subcutaneous depot using Camurus' FluidCrystal® technology.

Conditions

  • Polycystic Liver Disease

Interventions

  • CAM2029Drug

    SC injection using a pre-filled pen

  • PlaceboDrug

    SC injection using a pre-filled pen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height-adjusted Total Liver Volume (htTLV)Time frame: From screening until treatment week 53

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

  • Mount Sinai Hospital

    New York, New York

  • The New York Presbyterian Hospital

    New York, New York

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Bon Secours Richmond Community Hospital

    Richmond, Virginia

  • University Hospitals KU Leuven

    Leuven, Belgium

  • Hannover Medical School

    Hanover, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Germany

  • Universitaetsklinikum Müenster

    Münster, Germany

  • Radboud UMC, Department of Gastroenterology and Hepatology

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.